Skip to main content
S&P 5007,805.16-0.08%DOW51,900.12+0.47%NASDAQ27,268.67-0.36%BTC$82,775.00-0.37%ETH$2,528.09+0.91%GOLD$4,188.80-0.65%OIL$93.92+2.25%
Smart Investors Daily
SID Premium
AR

OTC · ARTH

Arch Therapeutics, Inc.

Healthcare · Biotechnology

$0.00

Up+$0.00 (+0.00%)

Updated Oct 12, 2026, 2:44 PM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
444
P/E ratio
-0
Dividend yield
0.00%
52-week range
— – —
Volume
1
Avg. volume
2.12K

Price performance · ARTH

ARTH price history

1M range · 0 trading sessions · Daily adjusted prices

ARTH does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ARTH news

The latest Smart Investors Daily articles mentioning ARTH.

Stock researchCompany · Overview

ARTH research

Overview

Company profile and research snapshot.

Company profile

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ARTH recent ratings
DateFirmRatingTarget
Jul 27, 2020HC Wainwright & Co.Buy—
Mar 14, 2018IFS SecuritiesOutperform—
Feb 13, 2017Rodman & RenshawBuy—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Dec 5, 2025

Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)

Arch Therapeutics (OTCMKTS:ARTH - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk. Volatility and Risk Arch Therapeutics has a beta

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By